Mark Glickman

Mark Glickman is President & CEO of BioFlorida, a statewide organization dedicated to advancing Florida’s life sciences industry. He leads BioFlorida’s strategy to strengthen the state’s position as a global life sciences hub by supporting member companies, fostering a strong business and legislative environment, and advancing research commercialization and innovation. Mr. Glickman previously served as Co-Chief Executive Officer of TherapeuticsMD, Inc. (NASDAQ: TXMD) through the sale of its assets to Mayne Therapeutics in January 2023. Prior to that, he was Chief Business Officer, Commercial at TherapeuticsMD and Chief Commercial Officer at Esperion Therapeutics, where he led the launch of the company’s first cardiovascular therapy. Earlier in his career, he held senior leadership roles at Aralez Pharmaceuticals, Auxilium (Endo), Otsuka America Pharmaceuticals, and Kos Pharmaceuticals (Abbott Labs). Mr. Glickman has more than 30 years of experience in the pharmaceutical and medical device industries. He holds a B.A. from SUNY Oswego and an MBA from NYU’s Stern School of Business and serves on the Board of Directors for MetaVia and Otsuka Precision Health.